Die Misteltherapie in der Onkologie
Tóm tắt
Từ khóa
Tài liệu tham khảo
Kienle GS, Kiene H, Albonico H. Anthroposophische Medizin in der klinischen Forschung. Stuttgart: Schattauer GmbH; 2006.
Rostock M. Misteltherapie: Ihr aktueller Stellenwert bei der Behandlung von Tumorerkrankungen. In: Phytopharmaka VI. Rietbrock N, Edts. Darmstadt: Steinkopff Verlag; 2000. S. 167–80.
Hoffmann F. Versorgung mit Krebstherapeutika im Jahr 2010. In: Barmer GEK Arzneimittelreport 2011; Glaeske G, Schicktanz C, Edts. Schriftreihe zur Gesundheitsanalyse, Band 8. Schwäbisch Gmünd: Barmer GEK; 2011.
Templeton A et al. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC Cancer. 2013;13:153.
Bopp A. Die Mistel — Heilpflanze in der Krebstherapie. Zürich: rüffer&rub Sachbuchverlag; 2006.
Kienle GS, Keine H. Die Mistel in der Onkologie. Stuttgart: Schattauer GmbH; 2003.
Buessing A. Mistletoe. The Genus Viscum. Amsterdam: Hardwood Academic Publishers; 2000.
Marvibaigi M et al. Preclinical and clinical effects of mistletoe against breast cancer. Biomed Res Int. 2014;2014:785479.
Tröger W et al. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe-a randomized controlled trial. Dtsch Arztebl Int. 2014;111(29-30):493–502.
Tröger W et al. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer. 2013;49(18):3788–97.
Bock PR et al. Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patients. Inflamm Allergy Drug Targets. 2014;13(2):105–11.
Matthes H. et al (2000) Endoscopic Ultrasound-Guided Fine -Needle Injection of Viscum album in the therapy of Primary Inoperable Pancreas cancer: a pilot study. Gastroenterology. 2005;128:433.
Tröger W et al. Quality of life and Neutropenia in Patients with Early stage Breast Cancer: A Randomized Pitot Study Comparing Additional Treatment with Mistletoe Extract to Chemotherapy Alone. Breast Cancer (Auckl). 2009;3:35–45.
Steele M et al. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients. Evid Based Complement Alternat Med. 2014;2014:724258.
Axtner J et al. Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer. BMC Cancer. 2016;16:579.
Tröger W et al. Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial. Evid Based Complement Alternat Med. 2014;2014:430518.
Kienle GS, Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther. 2010;9(2):142–57.
Buessing A et al. Quality of life and related dimensions in cancer patients treated with mistletoe extract (Iscador): a meta-analysis. Evid Based Complement Alternat Med. 2012;2012:219402.
Kienle G. Natum Mitteilung: Misteltherapie bei Krebs — was ist belegt, was nicht? Gynäkologie+Geburtshilfe. 2009;11:52–3.
Friedel WE et al. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo-and/or radiotherapy protocols and long term mistletoe application in nonmetastatic colorectal carcinoma: multicenter controlled, observational cohort study. J Soc Integr Oncol. 2009;7(4):137–45.
Pae HO et al. Potentiation of tumor necrosis- a -induced apoptosis by mistletoe lectin. Immunopharmacol Immunotoxicol. 2000;22(4):697–709.
Kuttan G, Kuttan R. Reduction of leucopenia in mice by „Viscum album“ administration during radiation and chemotherapy. Tumori. 1993;79(1):74–6.
Beuth J et al. Immunoprotective activity of the galactoside-specific mistletoe lectin in cortisone-treated BALB/c-mice. In Vivo. 1994;8(6):989–92.
Hajto T et al. Increased secretion of tumor necrosis factor a, interleukin 1 and interleukin 6 by human mononuclear cells exposed to ß-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res. 1990;50(11):3322–6.
Kleeberg UR et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer. 2004;40(3):390–402.
Burkhart J et al. In vitro investigation into the potential of a mistletoe extract to alleviate adverse effects of cyclophosphamide. Altern Ther Health Med. 2010;16(3):40–8.
Weissenstein U et al. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Complement Altern Med. 2016;16:271.
Schad F et al. Safety of combined treatment with monoclonal antibodies and Viscum album L. preparations. Integr Cancer Ther. 2018;17(1):41–51.
Bar-Sela G et al. Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer. 2013;49(5):1058–64.
Kienle GS et al. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res. 2009;28:79.
Matthes H et al. Integrative Therapiemöglichkeiten des inoperablen Pankreaskarzinoms- eine Übersicht. Deutsch Zeitschr Onkol. 2008;40(3):106–10.
Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreas cancer. N Engl J Med. 2011;364(19):1817–25.
Bock PR et al. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland]. Arzneimittelforschung. 2004;54(8):456–66.